

**EXHIBIT A**  
**THE CLAIMS WHICH WILL BE PENDING**  
**UPON ENTRY OF THE PRESENT AMENDMENT**  
**(Filed August 20, 2002)**  
**U.S. PATENT APPLICATION NO. 09/992,107**

23. A pharmaceutical composition for the treatment of atherosclerosis, hyperlipidemia, or hypoalphalipoproteinemia, comprising a therapeutically effective amount of unilamellar liposomes consisting essentially of phospholipids having an average diameter greater than about 100 nm obtainable by extruding phospholipids through filters.

24. The pharmaceutical composition of claim 23 wherein the liposomes have an average diameter of about 100 nm to about 150 nm.

25. The pharmaceutical composition of claim 23 wherein the liposomes have an average diameter of about  $114 \pm 7$  nm.

26. The pharmaceutical composition of claim 23 further comprising a pharmaceutically acceptable carrier.

27. The pharmaceutical composition of claim 26 wherein the pharmaceutically acceptable carrier is selected from the group consisting of sterilized water, sterilized buffered water, sterilized saline solution, and a sterilized aqueous solution containing a compound selected from the group consisting of glycine, glycoproteins, albumin, lipoprotein, globulin, pH adjusting agents, buffering agents, tonicity adjusting agents, sodium acetate, sodium lactate, potassium chloride, calcium chloride, sodium chloride, and mixtures thereof.

28. The pharmaceutical composition of claim 26 wherein the composition is lyophilized.

29. The pharmaceutical composition of claim 26 wherein the concentration of liposomes in the carrier is about 200 mg/ml.